+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Neuropathic Pain Drug Market by Product Type, Route of Administration, Distribution Channel, Indication, End User - Global Forecast to 2030- Product Image
Neuropathic Pain Drug Market by Product Type, Route of Administration, Distribution Channel, Indication, End User - Global Forecast to 2030- Product Image
Sale

Neuropathic Pain Drug Market by Product Type, Route of Administration, Distribution Channel, Indication, End User - Global Forecast to 2030

  • PDF Icon

    Report

  • 184 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 4968619
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The neuropathic pain drug market is evolving rapidly, shaped by advances in pharmacology, digital health integration, and proactive responses to shifting global supply and regulatory environments. Senior leaders navigating this sector require decisive insights into innovation, competitive positioning, and risk management across the complex treatment and procurement landscape.

Market Snapshot: Neuropathic Pain Drug Market

The Neuropathic Pain Drug Market grew from USD 12.90 billion in 2024 to USD 14.22 billion in 2025. It is expected to continue growing at a CAGR of 10.14%, reaching USD 23.04 billion by 2030. Market dynamics are charting significant momentum as stakeholder engagement deepens and R&D pipelines expand. As leading and emerging pharmaceutical companies drive the sector forward, new therapies, regulatory adaptations, and strategic partnerships are reshaping both immediate opportunities and long-term value creation.

Scope & Segmentation

  • Product Types: Anticonvulsants (carbamazepine, gabapentin, lamotrigine, pregabalin), antidepressants (SNRIs such as duloxetine and venlafaxine, TCAs like amitriptyline and nortriptyline), opioids (tapentadol, tramadol), and topical agents (capsaicin, diclofenac gel, lidocaine patch).
  • Routes of Administration: Intravenous, oral, topical, transdermal.
  • Distribution Channels: Chain retail, direct online, independent retail, private hospital, public hospital, third-party online.
  • Indications: Chemotherapy-induced neuropathy, diabetic neuropathy, HIV-associated neuropathy, post-herpetic neuralgia.
  • End Users: Home healthcare, hospitals, retail pharmacies, specialty clinics.
  • Regional Coverage: Americas (including the United States, Canada, Mexico, Brazil, Argentina), Europe, Middle East & Africa (such as the United Kingdom, Germany, France, Saudi Arabia, South Africa, and others), and Asia-Pacific (highlighting China, India, Japan, Australia, South Korea, and extended Southeast Asian markets).
  • Key Market Players: Representative companies include Pfizer Inc., Teva Pharmaceutical Industries Ltd., Mylan N.V., Novartis AG, Eli Lilly and Company, Grünenthal GmbH, Endo International plc, Bausch Health Companies Inc., Hikma Pharmaceuticals PLC, and AcelRx Therapeutics, Inc.

Key Takeaways

  • Innovative non-opioid therapies and next-generation drug modalities are diversifying treatment options and driving differentiation among traditional and emerging pharmaceutical companies.
  • Regulatory bodies are more receptive to accelerated approval pathways and are encouraging the adoption of precision medicine and digital monitoring for real-world evidence generation.
  • Strategic alliances between large pharma, biotech firms, and academic partners are expediting translational research and clinical trial optimization, resulting in improved drug development timelines and reduced costs.
  • The role of patient-centric digital platforms has heightened, enabling remote monitoring and adherence tracking that facilitate value-based contracting and outcomes-based reimbursement models.
  • Supply chain resilience and localization have become priorities in response to global disruption risk and emerging cost pressures, especially in regions subjected to tariff-driven regulatory shifts.

Tariff Impact on Neuropathic Pain Drug Market

New import tariffs in the United States, scheduled for 2025, are expected to increase manufacturing and acquisition costs across the neuropathic pain drug supply chain. Manufacturers are recalibrating sourcing and pricing models to adapt, with shifts toward domestic production and supply chain diversification accelerating. Stakeholders are exploring regulatory relief and seeking carve-outs for critical therapies, while payers evaluate value-based pricing to contain reimbursement impacts. Companies are advised to develop scenarios for inventory management, diversified ingredient sourcing, and flexible contracting to strengthen market positioning amid evolving cost dynamics.

Methodology & Data Sources

This report leverages primary research—including interviews with neurologists, pain specialists, regulatory experts, pharmacists, payers, and patient advocates—with secondary sources comprising peer-reviewed journals, regulatory filings, and industry white papers. Advanced data triangulation ensures reliability, and thematic coding distills actionable trends for decision-makers.

Why This Report Matters

  • Delivers actionable insights to optimize portfolio diversification and capitalize on growth opportunities in neuropathic pain drug development.
  • Equips senior leaders with clear intelligence on market segmentation, regional nuances, and the impact of evolving regulatory and cost structures.
  • Supports robust strategic planning through evidence-based findings—empowering more agile responses to global market complexity.

Conclusion

The neuropathic pain drug market stands at a pivotal point, shaped by scientific innovation, regulatory shifts, and new models of patient care. Leaders who align strategies with these insights are well-placed to unlock sustained growth amid emerging industry challenges and opportunities.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Neuropathic Pain Drug Market, by Product Type
8.1. Introduction
8.2. Anticonvulsants
8.2.1. Carbamazepine
8.2.2. Gabapentin
8.2.3. Lamotrigine
8.2.4. Pregabalin
8.3. Antidepressants
8.3.1. SNRIs
8.3.1.1. Duloxetine
8.3.1.2. Venlafaxine
8.3.2. TCAs
8.3.2.1. Amitriptyline
8.3.2.2. Nortriptyline
8.4. Opioids
8.4.1. Tapentadol
8.4.2. Tramadol
8.5. Topical Agents
8.5.1. Capsaicin
8.5.2. Diclofenac Gel
8.5.3. Lidocaine Patch
9. Neuropathic Pain Drug Market, by Route of Administration
9.1. Introduction
9.2. Intravenous
9.3. Oral
9.4. Topical
9.5. Transdermal
10. Neuropathic Pain Drug Market, by Distribution Channel
10.1. Introduction
10.2. Chain Retail
10.3. Direct Online
10.4. Independent Retail
10.5. Private Hospital
10.6. Public Hospital
10.7. Third Party Online
11. Neuropathic Pain Drug Market, by Indication
11.1. Introduction
11.2. Chemotherapy-Induced Neuropathy
11.3. Diabetic Neuropathy
11.4. HIV-Associated Neuropathy
11.5. Post-Herpetic Neuralgia
12. Neuropathic Pain Drug Market, by End User
12.1. Introduction
12.2. Home Healthcare
12.3. Hospitals
12.4. Retail Pharmacies
12.5. Specialty Clinics
13. Americas Neuropathic Pain Drug Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Neuropathic Pain Drug Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Neuropathic Pain Drug Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. Pfizer Inc.
16.3.2. Teva Pharmaceutical Industries Ltd.
16.3.3. Mylan N.V.
16.3.4. Novartis AG
16.3.5. Eli Lilly and Company
16.3.6. Grünenthal GmbH
16.3.7. Endo International plc
16.3.8. Bausch Health Companies Inc.
16.3.9. Hikma Pharmaceuticals PLC
16.3.10. AcelRx Therapeutics, Inc.
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. NEUROPATHIC PAIN DRUG MARKET MULTI-CURRENCY
FIGURE 2. NEUROPATHIC PAIN DRUG MARKET MULTI-LANGUAGE
FIGURE 3. NEUROPATHIC PAIN DRUG MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 12. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2024 VS 2030 (%)
FIGURE 14. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 16. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS NEUROPATHIC PAIN DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS NEUROPATHIC PAIN DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC NEUROPATHIC PAIN DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC NEUROPATHIC PAIN DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. NEUROPATHIC PAIN DRUG MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. NEUROPATHIC PAIN DRUG MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. NEUROPATHIC PAIN DRUG MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTICONVULSANTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY CARBAMAZEPINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY GABAPENTIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY LAMOTRIGINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY PREGABALIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTICONVULSANTS, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY SNRIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY DULOXETINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY VENLAFAXINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY SNRIS, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY TCAS, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY AMITRIPTYLINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY NORTRIPTYLINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY TCAS, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY OPIOIDS, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY TAPENTADOL, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY TRAMADOL, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY TOPICAL AGENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY CAPSAICIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY DICLOFENAC GEL, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY LIDOCAINE PATCH, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY TOPICAL AGENTS, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY TOPICAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY TRANSDERMAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY CHAIN RETAIL, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY DIRECT ONLINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDEPENDENT RETAIL, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY PRIVATE HOSPITAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY PUBLIC HOSPITAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY THIRD PARTY ONLINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY CHEMOTHERAPY-INDUCED NEUROPATHY, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY DIABETIC NEUROPATHY, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY HIV-ASSOCIATED NEUROPATHY, BY REGION, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY POST-HERPETIC NEURALGIA, BY REGION, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 54. AMERICAS NEUROPATHIC PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 55. AMERICAS NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTICONVULSANTS, 2018-2030 (USD MILLION)
TABLE 56. AMERICAS NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2030 (USD MILLION)
TABLE 57. AMERICAS NEUROPATHIC PAIN DRUG MARKET SIZE, BY SNRIS, 2018-2030 (USD MILLION)
TABLE 58. AMERICAS NEUROPATHIC PAIN DRUG MARKET SIZE, BY TCAS, 2018-2030 (USD MILLION)
TABLE 59. AMERICAS NEUROPATHIC PAIN DRUG MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
TABLE 60. AMERICAS NEUROPATHIC PAIN DRUG MARKET SIZE, BY TOPICAL AGENTS, 2018-2030 (USD MILLION)
TABLE 61. AMERICAS NEUROPATHIC PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 62. AMERICAS NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 63. AMERICAS NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 64. AMERICAS NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 65. AMERICAS NEUROPATHIC PAIN DRUG MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 66. UNITED STATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 67. UNITED STATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTICONVULSANTS, 2018-2030 (USD MILLION)
TABLE 68. UNITED STATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2030 (USD MILLION)
TABLE 69. UNITED STATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY SNRIS, 2018-2030 (USD MILLION)
TABLE 70. UNITED STATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY TCAS, 2018-2030 (USD MILLION)
TABLE 71. UNITED STATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
TABLE 72. UNITED STATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY TOPICAL AGENTS, 2018-2030 (USD MILLION)
TABLE 73. UNITED STATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 74. UNITED STATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 75. UNITED STATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 76. UNITED STATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 77. UNITED STATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 78. CANADA NEUROPATHIC PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 79. CANADA NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTICONVULSANTS, 2018-2030 (USD MILLION)
TABLE 80. CANADA NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2030 (USD MILLION)
TABLE 81. CANADA NEUROPATHIC PAIN DRUG MARKET SIZE, BY SNRIS, 2018-2030 (USD MILLION)
TABLE 82. CANADA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TCAS, 2018-2030 (USD MILLION)
TABLE 83. CANADA NEUROPATHIC PAIN DRUG MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
TABLE 84. CANADA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TOPICAL AGENTS, 2018-2030 (USD MILLION)
TABLE 85. CANADA NEUROPATHIC PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 86. CANADA NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 87. CANADA NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 88. CANADA NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 89. MEXICO NEUROPATHIC PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 90. MEXICO NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTICONVULSANTS, 2018-2030 (USD MILLION)
TABLE 91. MEXICO NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2030 (USD MILLION)
TABLE 92. MEXICO NEUROPATHIC PAIN DRUG MARKET SIZE, BY SNRIS, 2018-2030 (USD MILLION)
TABLE 93. MEXICO NEUROPATHIC PAIN DRUG MARKET SIZE, BY TCAS, 2018-2030 (USD MILLION)
TABLE 94. MEXICO NEUROPATHIC PAIN DRUG MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
TABLE 95. MEXICO NEUROPATHIC PAIN DRUG MARKET SIZE, BY TOPICAL AGENTS, 2018-2030 (USD MILLION)
TABLE 96. MEXICO NEUROPATHIC PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 97. MEXICO NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 98. MEXICO NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 99. MEXICO NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 100. BRAZIL NEUROPATHIC PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 101. BRAZIL NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTICONVULSANTS, 2018-2030 (USD MILLION)
TABLE 102. BRAZIL NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2030 (USD MILLION)
TABLE 103. BRAZIL NEUROPATHIC PAIN DRUG MARKET SIZE, BY SNRIS, 2018-2030 (USD MILLION)
TABLE 104. BRAZIL NEUROPATHIC PAIN DRUG MARKET SIZE, BY TCAS, 2018-2030 (USD MILLION)
TABLE 105. BRAZIL NEUROPATHIC PAIN DRUG MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
TABLE 106. BRAZIL NEUROPATHIC PAIN DRUG MARKET SIZE, BY TOPICAL AGENTS, 2018-2030 (USD MILLION)
TABLE 107. BRAZIL NEUROPATHIC PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 108. BRAZIL NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 109. BRAZIL NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 110. BRAZIL NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 111. ARGENTINA NEUROPATHIC PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 112. ARGENTINA NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTICONVULSANTS, 2018-2030 (USD MILLION)
TABLE 113. ARGENTINA NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2030 (USD MILLION)
TABLE 114. ARGENTINA NEUROPATHIC PAIN DRUG MARKET SIZE, BY SNRIS, 2018-2030 (USD MILLION)
TABLE 115. ARGENTINA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TCAS, 2018-2030 (USD MILLION)
TABLE 116. ARGENTINA NEUROPATHIC PAIN DRUG MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
TABLE 117. ARGENTINA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TOPICAL AGENTS, 2018-2030 (USD MILLION)
TABLE 118. ARGENTINA NEUROPATHIC PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 119. ARGENTINA NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 120. ARGENTINA NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 121. ARGENTINA NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 122. EUROPE, MIDDLE EAST & AFRICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 123. EUROPE, MIDDLE EAST & AFRICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTICONVULSANTS, 2018-2030 (USD MILLION)
TABLE 124. EUROPE, MIDDLE EAST & AFRICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2030 (USD MILLION)
TABLE 125. EUROPE, MIDDLE EAST & AFRICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY SNRIS, 2018-2030 (USD MILLION)
TABLE 126. EUROPE, MIDDLE EAST & AFRICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TCAS, 2018-2030 (USD MILLION)
TABLE 127. EUROPE, MIDDLE EAST & AFRICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
TABLE 128. EUROPE, MIDDLE EAST & AFRICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TOPICAL AGENTS, 2018-2030 (USD MILLION)
TABLE 129. EUROPE, MIDDLE EAST & AFRICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 130. EUROPE, MIDDLE EAST & AFRICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 131. EUROPE, MIDDLE EAST & AFRICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 132. EUROPE, MIDDLE EAST & AFRICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 133. EUROPE, MIDDLE EAST & AFRICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 134. UNITED KINGDOM NEUROPATHIC PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 135. UNITED KINGDOM NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTICONVULSANTS, 2018-2030 (USD MILLION)
TABLE 136. UNITED KINGDOM NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2030 (USD MILLION)
TABLE 137. UNITED KINGDOM NEUROPATHIC PAIN DRUG MARKET SIZE, BY SNRIS, 2018-2030 (USD MILLION)
TABLE 138. UNITED KINGDOM NEUROPATHIC PAIN DRUG MARKET SIZE, BY TCAS, 2018-2030 (USD MILLION)
TABLE 139. UNITED KINGDOM NEUROPATHIC PAIN DRUG MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
TABLE 140. UNITED KINGDOM NEUROPATHIC PAIN DRUG MARKET SIZE, BY TOPICAL AGENTS, 2018-2030 (USD MILLION)
TABLE 141. UNITED KINGDOM NEUROPATHIC PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 142. UNITED KINGDOM NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 143. UNITED KINGDOM NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 144. UNITED KINGDOM NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 145. GERMANY NEUROPATHIC PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 146. GERMANY NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTICONVULSANTS, 2018-2030 (USD MILLION)
TABLE 147. GERMANY NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2030 (USD MILLION)
TABLE 148. GERMANY NEUROPATHIC PAIN DRUG MARKET SIZE, BY SNRIS, 2018-2030 (USD MILLION)
TABLE 149. GERMANY NEUROPATHIC PAIN DRUG MARKET SIZE, BY TCAS, 2018-2030 (USD MILLION)
TABLE 150. GERMANY NEUROPATHIC PAIN DRUG MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
TABLE 151. GERMANY NEUROPATHIC PAIN DRUG MARKET SIZE, BY TOPICAL AGENTS, 2018-2030 (USD MILLION)
TABLE 152. GERMANY NEUROPATHIC PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 153. GERMANY NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 154. GERMANY NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 155. GERMANY NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 156. FRANCE NEUROPATHIC PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 157. FRANCE NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTICONVULSANTS, 2018-2030 (USD MILLION)
TABLE 158. FRANCE NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2030 (USD MILLION)
TABLE 159. FRANCE NEUROPATHIC PAIN DRUG MARKET SIZE, BY SNRIS, 2018-2030 (USD MILLION)
TABLE 160. FRANCE NEUROPATHIC PAIN DRUG MARKET SIZE, BY TCAS, 2018-2030 (USD MILLION)
TABLE 161. FRANCE NEUROPATHIC PAIN DRUG MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
TABLE 162. FRANCE NEUROPATHIC PAIN DRUG MARKET SIZE, BY TOPICAL AGENTS, 2018-2030 (USD MILLION)
TABLE 163. FRANCE NEUROPATHIC PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 164. FRANCE NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 165. FRANCE NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 166. FRANCE NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 167. RUSSIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 168. RUSSIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTICONVULSANTS, 2018-2030 (USD MILLION)
TABLE 169. RUSSIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2030 (USD MILLION)
TABLE 170. RUSSIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY SNRIS, 2018-2030 (USD MILLION)
TABLE 171. RUSSIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TCAS, 2018-2030 (USD MILLION)
TABLE 172. RUSSIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
TABLE 173. RUSSIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TOPICAL AGENTS, 2018-2030 (USD MILLION)
TABLE 174. RUSSIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 175. RUSSIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 176. RUSSIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 177. RUSSIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 178. ITALY NEUROPATHIC PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 179. ITALY NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTICONVULSANTS, 2018-2030 (USD MILLION)
TABLE 180. ITALY NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2030 (USD MILLION)
TABLE 181. ITALY NEUROPATHIC PAIN DRUG MARKET SIZE, BY SNRIS, 2018-2030 (USD MILLION)
TABLE 182. ITALY NEUROPATHIC PAIN DRUG MARKET SIZE, BY TCAS, 2018-2030 (USD MILLION)
TABLE 183. ITALY NEUROPATHIC PAIN DRUG MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
TABLE 184. ITALY NEUROPATHIC PAIN DRUG MARKET SIZE, BY TOPICAL AGENTS, 2018-2030 (USD MILLION)
TABLE 185. ITALY NEUROPATHIC PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 186. ITALY NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 187. ITALY NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 188. ITALY NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 189. SPAIN NEUROPATHIC PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 190. SPAIN NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTICONVULSANTS, 2018-2030 (USD MILLION)
TABLE 191. SPAIN NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2030 (USD MILLION)
TABLE 192. SPAIN NEUROPATHIC PAIN DRUG MARKET SIZE, BY SNRIS, 2018-2030 (USD MILLION)
TABLE 193. SPAIN NEUROPATHIC PAIN DRUG MARKET SIZE, BY TCAS, 2018-2030 (USD MILLION)
TABLE 194. SPAIN NEUROPATHIC PAIN DRUG MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
TABLE 195. SPAIN NEUROPATHIC PAIN DRUG MARKET SIZE, BY TOPICAL AGENTS, 2018-2030 (USD MILLION)
TABLE 196. SPAIN NEUROPATHIC PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 197. SPAIN NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 198. SPAIN NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 199. SPAIN NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 200. UNITED ARAB EMIRATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 201. UNITED ARAB EMIRATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTICONVULSANTS, 2018-2030 (USD MILLION)
TABLE 202. UNITED ARAB EMIRATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2030 (USD MILLION)
TABLE 203. UNITED ARAB EMIRATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY SNRIS, 2018-2030 (USD MILLION)
TABLE 204. UNITED ARAB EMIRATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY TCAS, 2018-2030 (USD MILLION)
TABLE 205. UNITED ARAB EMIRATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
TABLE 206. UNITED ARAB EMIRATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY TOPICAL AGENTS, 2018-2030 (USD MILLION)
TABLE 207. UNITED ARAB EMIRATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 208. UNITED ARAB EMIRATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 209. UNITED ARAB EMIRATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 210. UNITED ARAB EMIRATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 211. SAUDI ARABIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 212. SAUDI ARABIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTICONVULSANTS, 2018-2030 (USD MILLION)
TABLE 213. SAUDI ARABIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2030 (USD MILLION)
TABLE 214. SAUDI ARABIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY SNRIS, 2018-2030 (USD MILLION)
TABLE 215. SAUDI ARABIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TCAS, 2018-2030 (USD MILLION)
TABLE 216. SAUDI ARABIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
TABLE 217. SAUDI ARABIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TOPICAL AGENTS, 2018-2030 (USD MILLION)
TABLE 218. SAUDI ARABIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 219. SAUDI ARABIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 220. SAUDI ARABIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 221. SAUDI ARABIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 222. SOUTH AFRICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 223. SOUTH AFRICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTICONVULSANTS, 2018-2030 (USD MILLION)
TABLE 224. SOUTH AFRICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2030 (USD MILLION)
TABLE 225. SOUTH AFRICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY SNRIS, 2018-2030 (USD MILLION)
TABLE 226. SOUTH AFRICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TCAS, 2018-2030 (USD MILLION)
TABLE 227. SOUTH AFRICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
TABLE 228. SOUTH AFRICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TOPICAL AGENTS, 2018-2030 (USD MILLION)
TABLE 229. SOUTH AFRICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 230. SOUTH AFRICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 231. SOUTH AFRICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 232. SOUTH AFRICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 233. DENMARK NEUROPATHIC PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 234. DENMARK NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTICONVULSANTS, 2018-2030 (USD MILLION)
TABLE 235. DENMARK NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2030 (USD MILLION)
TABLE 236. DENMARK NEUROPATHIC PAIN DRUG MARKET SIZE, BY SNRIS, 2018-2030 (USD MILLION)
TABLE 237. DENMARK NEUROPATHIC PAIN DRUG MARKET SIZE, BY TCAS, 2018-2030 (USD MILLION)
TABLE 238. DENMARK NEUROPATHIC PAIN DRUG MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
TABLE 239. DENMARK NEUROPATHIC PAIN DRUG MARKET SIZE, BY TOPICAL AGENTS, 2018-2030 (USD MILLION)
TABLE 240. DENMARK NEUROPATHIC PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 241. DENMARK NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 242. DENMARK NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 243. DENMARK NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 244. NETHERLANDS NEUROPATHIC PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 245. NETHERLANDS NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTICONVULSANTS, 2018-2030 (USD MILLION)
TABLE 246. NETHERLANDS NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2030 (USD MILLION)
TABLE 247. NETHERLANDS NEUROPATHIC PAIN DRUG MARKET SIZE, BY SNRIS, 2018-2030 (USD MILLION)
TABLE 248. NETHERLANDS NEUROPATHIC PAIN DRUG MARKET SIZE, BY TCAS, 2018-2030 (USD MILLION)
TABLE 249. NETHERLANDS NEUROPATHIC PAIN DRUG MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
TABLE 250. NETHERLANDS NEUROPATHIC PAIN DRUG MARKET SIZE, BY TOPICAL AGENTS, 2018-2030 (USD MILLION)
TABLE 251. NETHERLANDS NEUROPATHIC PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 252. NETHERLANDS NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 253. NETHERLANDS NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 254. NETHERLANDS NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 255. QATAR NEUROPATHIC PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 256. QATAR NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTICONVULSANTS, 2018-2030 (USD MILLION)
TABLE 257. QATAR NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2030 (USD MILLION)
TABLE 258. QATAR NEUROPATHIC PAIN DRUG MARKET SIZE, BY SNRIS, 2018-2030 (USD MILLION)
TABLE 259. QATAR NEUROPATHIC PAIN DRUG MARKET SIZE, BY TCAS, 2018-2030 (USD MILLION)
TABLE 260. QATAR NEUROPATHIC PAIN DRUG MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
TABLE 261. QATAR NEUROPATHIC PAIN DRUG MARKET SIZE, BY TOPICAL AGENTS, 2018-2030 (USD MILLION)
TABLE 262. QATAR NEUROPATHIC PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 263. QATAR NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 264. QATAR NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 265. QATAR NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 266. FINLAND NEUROPATHIC PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 267. FINLAND NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTICONVULSANTS, 2018-2030 (USD MILLION)
TABLE 268. FINLAND NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2030 (USD MILLION)
TABLE 269. FINLAND NEUROPATHIC PAIN DRUG MARKET SIZE, BY SNRIS, 2018-2030 (USD MILLION)
TABLE 270. FINLAND NEUROPATHIC PAIN DRUG MARKET SIZE, BY TCAS, 2018-2030 (USD MILLION)
TABLE 271. FINLAND NEUROPATHIC PAIN DRUG MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
TABLE 272. FINLAND NEUROPATHIC PAIN DRUG MARKET SIZE, BY TOPICAL AGENTS, 2018-2030 (USD MILLION)
TABLE 273. FINLAND NEUROPATHIC PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 274. FINLAND NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 275. FINLAND NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 276. FINLAND NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 277. SWEDEN NEUROPATHIC PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 278. SWEDEN NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTICONVULSANTS, 2018-2030 (USD MILLION)
TABLE 279. SWEDEN NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2030 (USD MILLION)
TABLE 280. SWEDEN NEUROPATHIC PAIN DRUG MARKET SIZE, BY SNRIS, 2018-2030 (USD MILLION)
TABLE 281. SWEDEN NEUROPATHIC PAIN DRUG MARKET SIZE, BY TCAS, 2018-2030 (USD MILLION)
TABLE 282. SWEDEN NEUROPATHIC PAIN DRUG MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
TABLE 283. SWEDEN NEUROPATHIC PAIN DRUG MARKET SIZE, BY TOPICAL AGENTS, 2018-2030 (USD MILLION)
TABLE 284. SWEDEN NEUROPATHIC PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 285. SWEDEN NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 286. SWEDEN NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 287. SWEDEN NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 288. NIGERIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 289. NIGERIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTICONVULSANTS, 2018-2030 (USD MILLION)
TABLE 290. NIGERIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2030 (USD MILLION)
TABLE 291. NIGERIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY SNRIS, 2018-2030 (USD MILLION)
TABLE 292. NIGERIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TCAS, 2018-2030 (USD MILLION)
TABLE 293. NIGERIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
TABLE 294. NIGERIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TOPICAL AGENTS, 2018-2030 (USD MILLION)
TABLE 295. NIGERIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 296. NIGERIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 297. NIGERIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 298. NIGERIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 299. EGYPT NEUROPATHIC PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 300. EGYPT NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTICONVULSANTS, 2018-2030 (USD MILLION)
TABLE 301. EGYPT NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2030 (USD MILLION)
TABLE 302. EGYPT NEUROPATHIC PAIN DRUG MARKET SIZE, BY SNRIS, 2018-2030 (USD MILLION)
TABLE 303. EGYPT NEUROPATHIC PAIN DRUG MARKET SIZE, BY TCAS, 2018-2030 (USD MILLION)
TABLE 304. EGYPT NEUROPATHIC PAIN DRUG MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
TABLE 305. EGYPT NEUROPATHIC PAIN DRUG MARKET SIZE, BY TOPICAL AGENTS, 2018-2030 (USD MILLION)
TABLE 306. EGYPT NEUROPATHIC PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 307. EGYPT NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 308. EGYPT NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 309. EGYPT NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 310. TURKEY NEUROPATHIC PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 311. TURKEY NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTICONVULSANTS, 2018-2030 (USD MILLION)
TABLE 312. TURKEY NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2030 (USD MILLION)
TABLE 313. TURKEY NEUROPATHIC PAIN DRUG MARKET SIZE, BY SNRIS, 2018-2030 (USD MILLION)
TABLE 314. TURKEY NEUROPATHIC PAIN DRUG MARKET SIZE, BY TCAS, 2018-2030 (USD MILLION)
TABLE 315. TURKEY NEUROPATHIC PAIN DRUG MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
TABLE 316. TURKEY NEUROPATHIC PAIN DRUG MARKET SIZE, BY TOPICAL AGENTS, 2018-2030 (USD MILLION)
TABLE 317. TURKEY NEUROPATHIC PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 318. TURKEY NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 319. TURKEY NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 320. TURKEY NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 321. ISRAEL NEUROPATHIC PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 322. ISRAEL NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTICONVULSANTS, 2018-2030 (USD MILLION)
TABLE 323. ISRAEL NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2030 (USD MILLION)
TABLE 324. ISRAEL NEUROPATHIC PAIN DRUG MARKET SIZE, BY SNRIS, 2018-2030 (USD MILLION)
TABLE 325. ISRAEL NEUROPATHIC PAIN DRUG MARKET SIZE, BY TCAS, 2018-2030 (USD MILLION)
TABLE 326. ISRAEL NEUROPATHIC PAIN DRUG MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
TABLE 327. ISRAEL NEUROPATHIC PAIN DRUG MARKET SIZE, BY TOPICAL AGENTS, 2018-2030 (USD MILLION)
TABLE 328. ISRAEL NEUROPATHIC PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 329. ISRAEL NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 330. ISRAEL NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 331. ISRAEL NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 332. NORWAY NEUROPATHIC PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 333. NORWAY NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTICONVULSANTS, 2018-2030 (USD MILLION)
TABLE 334. NORWAY NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2030 (USD MILLION)
TABLE 335. NORWAY NEUROPATHIC PAIN DRUG MARKET SIZE, BY SNRIS, 2018-2030 (USD MILLION)
TABLE 336. NORWAY NEUROPATHIC PAIN DRUG MARKET SIZE, BY TCAS, 2018-2030 (USD MILLION)
TABLE 337. NORWAY NEUROPATHIC PAIN DRUG MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
TABLE 338.

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Neuropathic Pain Drug market report include:
  • Pfizer Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Mylan N.V.
  • Novartis AG
  • Eli Lilly and Company
  • Grünenthal GmbH
  • Endo International plc
  • Bausch Health Companies Inc.
  • Hikma Pharmaceuticals PLC
  • AcelRx Therapeutics, Inc.

Table Information

Report AttributeDetails
No. of Pages184
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 14.22 Billion
Forecasted Market Value ( USD ) by 2030 $ 23.04 Billion
Compound Annual Growth Rate10.1%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Diabetic Neuropathic Pain Market Report and Forecast 2025-2034 - Product Image

Diabetic Neuropathic Pain Market Report and Forecast 2025-2034

  • Report
  • 400 Pages
  • Global
From
Peripheral Neuropathic Pain-Pipeline Insight, 2025 - Product Image

Peripheral Neuropathic Pain-Pipeline Insight, 2025

  • Clinical Trials
  • 60 Pages
  • Global
From
Neuropathic Pain Drug Market Report: Trends, Forecast and Competitive Analysis to 2031 - Product Image

Neuropathic Pain Drug Market Report: Trends, Forecast and Competitive Analysis to 2031

  • Report
  • 150 Pages
  • Global
From
Neuropathic Pain Treatment Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025-2034 - Product Image

Neuropathic Pain Treatment Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025-2034

  • Report
  • 130 Pages
  • Global
From
Neuropathic Pain Market Report 2025 - Product Image

Neuropathic Pain Market Report 2025

  • Report
  • 200 Pages
  • Global
From

About the Neuropathic Pain Drug Market

The Neuropathic Pain Drug market is a subset of the Central Nervous System Drugs market, which includes drugs used to treat neurological disorders. Neuropathic pain drugs are used to treat chronic pain caused by nerve damage, such as diabetic neuropathy, postherpetic neuralgia, and trigeminal neuralgia. These drugs are typically divided into two categories: anticonvulsants and antidepressants. Anticonvulsants are used to reduce the intensity of nerve pain, while antidepressants are used to reduce the frequency of nerve pain. Commonly prescribed neuropathic pain drugs include pregabalin, gabapentin, duloxetine, and amitriptyline. Some companies in the Neuropathic Pain Drug market include Pfizer, GlaxoSmithKline, Eli Lilly, and Novartis. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.